The Evolving Therapeutic Paradigm in IBD: Optimal Positioning of New and Emerging Agents

The Evolving Therapeutic Paradigm in IBD: Optimal Positioning of New and Emerging Agents

On-Demand Webcast

Stephen B. Hanauer, MD
Professor of Medicine
Northwestern University
Chicago, IL

Intended Learners

This activity is designed for dermatologists, rheumatologists, gastroenterologists, immunologists, nurse practitioners, nurses, physician assistants, pharmacists and other healthcare professionals involved in the management of patients with autoimmune diseases.

Learning Objectives

After completing this activity, participants should be able to:

  • Describe the current understanding of IBD pathophysiology with respect to inflammatory signaling pathways and therapeutic targets
  • Evaluate the mechanisms of action and available efficacy and safety data surrounding new and emerging therapies for the treatment of IBD
  • Implement evidence-based approaches for selecting, monitoring, and adjusting treatment to achieve remission induction and maintenance in IBD
Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at, participants may immediately print their documentation of credit.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Participants who have successfully completed the live version of this activity (IAS 2020, July 10-12, 2020) are not eligible to receive credit for this enduring webcast.

Release date: August 1, 2020
Expiration date: August 1, 2021
Estimated time to complete: .75 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Jointly Accredited ProviderIn support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards .75 contact hour.


This activity is approved for .75 contact hour (0.075 CEU) of continuing pharmacy education (UAN JA0006201-0000-20-119-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation and Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Bret A. Lashner, MD, Director, Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Planning Committee

The planning committee comprises Stephen B. Hanauer, MD; Bret Lashner, MD; Susie Seaman, NP; and Chris Bolwell, Jennifer Browne, Shoshana Cenker, Samantha Conforti, Molly, Duda, Mary Johnson, Mike Kearney, Randy Robbin, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Hanauer: Consultant, Clinical Research (Institution), Speaker –AbbVie, Janssen, Pfizer, Takeda; Consultant, Clinical Research (Institution) – Allergan, Amgen, Celgene, Genentech, Gilead, Lilly, Prometheus, Receptos, UCB Pharma; Consultant, Speaker – Merck, Samsung Bioepis; Consultant – Boehringer Ingelheim, Celltrion, Hospira, Salix, Seres Health, Shire, Tigenex, VHsquared

Dr. Lashner has disclosed no relevant financial relationships with any commercial interests.

Ms. Seaman: Advisory Board—Mölnlycke

Ms. Browne, Ms. Cenker, Ms. Conforti, Ms. Duda, Ms. Johnson, Mr. Kearney, and Mr. Robbin, NACCME, have disclosed no relevant financial relationships with any commercial interests.

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by independent educational grants from AbbVie, Celgene Corporation, Genentech, a member of the Roche Group, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.